Adenosine A3 R Antibody

Western Blot: Adenosine A3 R Antibody [NLS689]

Western Blot: Adenosine A3 R Antibody [NLS689] - EGFR and adenosine signaling pathways are involved in CD73-dependent EMT in HNSCC cells (A) CAL27 cells were treated with siRNA targeting CD73 or control siRNA followed by incubation with MRS3588 for another 36 h. E-cadherin, N-cadherin, Vimentin and Slug levels were evaluated. GAPDH was the internal standard for protein loading. One-way ANOVA with post-Dunnett analysis was performed using GraphPad Prism5.*P < 0.05, versus the si-control group, #P < 0.05, versus the CD73-si group. (n = 3). Image collected and cropped by CiteAb from the following publication (www.oncotarget.com/article/11435/text/), licensed under a CC-BY license.

Immunohistochemistry-Paraffin: Adenosine A3 R Antibody [NLS689]

Immunohistochemistry-Paraffin: Adenosine A3 R Antibody [NLS689] - Analysis of anti-Adenosine A3 Receptor / ADORA3 antibody with human tonsil, squamous epithelium at dilution 20-30 ug/ml.

Immunohistochemistry: Adenosine A3 R Antibody [NLS689] -

Immunohistochemistry: Adenosine A3 R Antibody [NLS689] - si-CD73 inhibits HNSCC tumor growth & suppress EMT in vivo(A) Tumor growth curve of siRNA-CD73 mice & control mice. Data represent the mean ± SEM. of eight mice in each group. *P < 0.05, **P < 0.01, ***P < 0.001 by the Student's t-test; (B) Dissected tumors were photographed. The tumor volume & weight were measured. ***P < 0.001 by the Student's t-test; (C) Representative images of immunohistochemical analysis of CD73, p-EGFR, p-Src, A3R, Slug, E-cad, N-cad & Vimentin in tumors, (Scale bars = 100 μm). Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.11435), licensed under a CC-BY license. Not internally tested by Novus Biologicals.